[go: up one dir, main page]

AR130844A1 - Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos - Google Patents

Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos

Info

Publication number
AR130844A1
AR130844A1 ARP230102831A ARP230102831A AR130844A1 AR 130844 A1 AR130844 A1 AR 130844A1 AR P230102831 A ARP230102831 A AR P230102831A AR P230102831 A ARP230102831 A AR P230102831A AR 130844 A1 AR130844 A1 AR 130844A1
Authority
AR
Argentina
Prior art keywords
cancer
formula
hydrogen
compound
ch2nhc
Prior art date
Application number
ARP230102831A
Other languages
English (en)
Inventor
Vlad Bacauanu
Manoj B Charati
Sijie Chen
Rebecca Elizabeth Johnson
Simon B Lang
Christian L Morales
Ryan Quiroz
W Michael Seganish
Nancy S Zepeda
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of AR130844A1 publication Critical patent/AR130844A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere a enlazadores-cargas útiles y a sales (incluidas las sales farmacéuticamente aceptables), solvatos o estereoisómeros de los mismos, que comprenden una estructura de fórmula (1). La divulgación también se refiere a composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos, intermedios de los mismos y composiciones en la prevención o el tratamiento de cánceres y/o tumores. Reivindicación 1: Un compuesto que tiene una fórmula estructural (1) o una sal del mismo, en donde: Z se selecciona entre hidrógeno y -CH₂C(Rˣ)(Rʸ)CHF₂; Z¹ se selecciona entre -NH- y -O-; Z² está ausente o se selecciona entre -CRᵇRᵇ-, -CH₂CRᵇRᵇ-, y -CRᵇRᵇCH₂-; cada Rᵇ se selecciona independientemente entre hidrógeno, -alquilo C₁₋₆ e hidroxilo; o dos Rᵇ adyacentes se combinan para formar espirocicloalquilo; cada Rᶜ se selecciona independientemente entre hidrógeno, -alquilo C₁₋₆, halógeno e hidroxilo; o dos Rᶜ adyacentes se combinan para formar espirocicloalquilo; Rˣ y Rʸ se seleccionan independientemente entre hidrógeno, alquilo C₁₋₆, haloalquilo C₁₋₃, halógeno, hidroxilo y -alquil C₁₋₆-OH; o Rˣ y Rʸ se combinan para formar un cicloalquilo o espirocicloalquilo C₃₋₆; X es un grupo de enlace seleccionado entre: W1: de fórmula (2); W2: de fórmula (3); W3: de fórmula (4); W4: de fórmula (5); W5: de fórmula (6); W6: de fórmula (7); W7: de fórmula (8); y W8: de fórmula (9); ⁻⁻⁻⁻⁻⁻⁻ representa el punto de unión a la fórmula estructural (1); X¹ es un polietilenglicol (PEG); X³ es hidrógeno o -C(O)NRᵃRᶻ, X⁴ es hidrógeno o un resto de fórmula (10); Rᵃ y Rᶻ se seleccionan independientemente entre hidrógeno, alquilo C₁₋₆ y X¹, o Rᵃ y Rᶻ se combinan para formar un cicloalquilo C₃₋₁₀, o un heterociclilo de 3 a 10 miembros; Rᵈ es hidrógeno, -CH₂NHC(O)X¹ o -CH₂NHC(O)X¹Q; y Q es alquilo C₁₋₆ o hidrógeno. Reivindicación 25: Un compuesto de fórmula estructural (11) en donde: Rʲ se selecciona entre OH, -NH₂, -NHRᵏRᵍ, -NHRᵏNH(CH₂)ₙORq, -NHRᵏNH(CH₂)ₙOC(O)CH₃, -NHX¹ᵃ(CH₂)ₙC(O)RᵏNHCH₂OC(O)CH₃, -NHRᵏNHRL, -NHX¹ᵃRᵏNHRL, y -NHCH₂O(CH₂)ₙCH(OH)C(O)OH; Rᵍ es COOH o CONH₂; Rᵏ es un resto aminoacídico de hasta 10 aminoácidos; RL se selecciona entre: los compuestos de fórmulas (a), (b) o (c); Rᵖ se selecciona entre NH₂ y un resto de fórmula (12); Rq es hidrógeno o alquilo C₁₋₆; X¹ᵃ es un PEG de 1 a 24 subunidades de -CH₂CH₂O-; Rᵈ¹ es hidrógeno, -CH₂NHC(O)X¹ᵃQ o -CH₂NHC(O)X²¹Q; Q es alquilo C₁₋₆ o H; X²¹ se selecciona entre un PEG de 1 a 24 subunidades de -CH₂CH₂O-, PEG-aminoazúcar, y p-aminobencilcarbonilo y n es 1, 2, 3 o 4. Reivindicación 30: Un método de tratamiento o prevención de un cáncer seleccionado entre cáncer de mama, cáncer de ovario, cáncer cervicouterino, cáncer de útero, cáncer de próstata, cáncer de riñón, cáncer de uretra, cáncer de vejiga, cáncer de hígado, cáncer de estómago, cáncer de endometrio, cáncer de las glándulas salivales, cáncer de esófago, melanoma, glioma, neuroblastoma, sarcoma, cáncer de pulmón, cáncer de colon, cáncer rectal, cáncer colorrectal, leucemia, cáncer óseo, melanoma maligno, cáncer de tiroides, cáncer pancreático y linfoma en un sujeto que lo necesite, comprendiendo dicho método administrar al sujeto que necesite dicho tratamiento una cantidad terapéuticamente eficaz de un compuesto de una cualquiera de las reivindicaciones 1 - 24, o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto, sal o solvato del mismo. Reivindicación 31: Un método para tratar y/o prevenir un tumor, que comprende administrar a un paciente que lo necesite una cantidad terapéuticamente eficaz del compuesto o la composición farmacéutica que comprende el compuesto de una cualquiera de las reivindicaciones 1 - 24 o una sal farmacéuticamente aceptable del mismo.
ARP230102831A 2022-10-25 2023-10-23 Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos AR130844A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263419150P 2022-10-25 2022-10-25

Publications (1)

Publication Number Publication Date
AR130844A1 true AR130844A1 (es) 2025-01-22

Family

ID=88779316

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102831A AR130844A1 (es) 2022-10-25 2023-10-23 Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos

Country Status (4)

Country Link
US (1) US20240208987A1 (es)
AR (1) AR130844A1 (es)
TW (1) TW202432099A (es)
WO (1) WO2024091437A1 (es)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
SE378110B (es) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU4086101A (en) 2000-03-20 2001-10-03 Merck Sharp & Dohme Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
GB0025173D0 (en) 2000-10-13 2000-11-29 Merck Sharp & Dohme Therapeutic agents
ES2248397T3 (es) 2000-11-02 2006-03-16 MERCK SHARP & DOHME LTD. Sulfamidas como inhibidores de la gamma-secretasa.
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
GB0108592D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
MXPA04001607A (es) 2001-08-21 2004-07-08 Merck Sharp & Dohme Ciclohexilsulfonas novedosas.
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
AU2003229932B2 (en) 2002-05-01 2008-12-11 Merck Sharp & Dohme Limited Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223040D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
DE602004011767T2 (de) 2003-05-16 2009-02-19 Merck Sharp & Dohme Ltd., Hoddesdon Cyclohexylsulfone als gamma-sekretase-inhibitoren
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
CA2539042A1 (en) 2003-09-24 2005-04-07 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
KR102052319B1 (ko) 2012-10-11 2019-12-05 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3858386A4 (en) 2018-09-26 2022-10-12 Jiangsu Hengrui Medicine Co., Ltd. LIGAND-DRUG CONJUGATE OF AN EXATECAN ANALOG, METHOD FOR PREPARATION AND THEIR USE
BR112022004913A2 (pt) 2019-09-18 2022-06-07 Baili Bio Chengdu Pharmaceutical Co Ltd Derivado de camptotecina e conjugado do mesmo
BR112022024930A2 (pt) * 2020-06-08 2022-12-27 Baili Bio Chengdu Pharmaceutical Co Ltd Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo
IL301004A (en) * 2020-09-04 2023-04-01 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
WO2022056696A1 (zh) * 2020-09-15 2022-03-24 四川百利药业有限责任公司 一种喜树碱类药物及其抗体偶联物
EP4516357A2 (en) 2020-09-30 2025-03-05 Duality Biologics (Suzhou) Co., Ltd. Antitumor, compound, and preparation method therefor and use thereof
US20240158410A1 (en) * 2021-02-05 2024-05-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
CN113816969B (zh) 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 依喜替康类化合物、其抗体药物偶联物及其应用

Also Published As

Publication number Publication date
WO2024091437A1 (en) 2024-05-02
US20240208987A1 (en) 2024-06-27
TW202432099A (zh) 2024-08-16

Similar Documents

Publication Publication Date Title
AR120080A1 (es) Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
JP6399930B2 (ja) ピロロベンゾジアゼピンおよび標的コンジュゲート
JP6170497B2 (ja) ピロロベンゾジアゼピン
JP6170494B2 (ja) ピロロベンゾジアゼピン
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
JP2014528466A (ja) ピロロベンゾジアゼピン
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
RU2217432C2 (ru) Эктеинасцидины, фармацевтическая композиция, содержащая их и способ лечения опухолей
JP2015517482A5 (es)
JP2015523326A5 (es)
AR117206A1 (es) Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
AR123049A1 (es) Compuestos terapéuticos y modos de uso
AR130844A1 (es) Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos
IL273387B2 (en) Thailanstatin analogs
AR129299A1 (es) Compuestos para modular complejos de factores asociados a brg1 o brm (baf)
JP2017529386A5 (es)
RU2225710C2 (ru) Списулозиновые соединения, обладающие противоопухолевой активностью
BR0308071A (pt) Inibidores da protéina farnesil transferase como agentes antitumores
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
AR125312A1 (es) Derivados heterocíclicos, composiciones farmacéuticas y su uso en el tratamiento o la mejora del cáncer
RU2015150994A (ru) Новые производные морфолинилантрациклина
AR119331A1 (es) Ligandos para el antígeno de membrana específico de próstata (psma) y usos de los mismos
AR114910A1 (es) Compuestos de pirimidina que contienen grupos ácidos
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.